Endocrine Therapy and Beyond
Thursday, May 1
8:00 AM–12:00 PM
8:00 AM–12:00 PM
Course Moderators: Ronda S. Henry-Tillman, MD, FACS; Julie A. Margenthaler, MD, FACS
Faculty: Amy Cyr, MD, FACS; Ronda S. Henry-Tillman, MD, FACS; Nathalie G. Johnson, MD, FACS; Julie A. Margenthaler, MD, FACS; Toan T. Nguyen, MD, FACS; Daniela A. Ochoa, MD, FACS; Anna Weiss, MD, FACS
Course Description:
Participants will learn the data supporting the use of both neoadjuvant and adjuvant endocrine therapy for patients with high risk and hormone-receptive breast cancer. There will also be a focus on surgeons as prescribers and managing patient side effects and potential complications.
Course Objectives:
At the conclusion of this course, participants should be able to:
- Discuss the indications for neoadjuvant endocrine therapy.
- Describe the adjuvant endocrine therapy options for pre- and post-menopausal patients.
- Identify and mitigate the side effects of endocrine therapy.
- Understand the data from the landmark trials of neoadjuvant and adjuvant endocrine therapy.
CME Credit Information:
This live activity has been approved for AMA PRA Category 1 Credit™. Check back for credit designation updates.
Onsite Agenda:
| 7:30 AM | Check-in and Breakfast
|
| 8:00 AM | Welcome and Introduction
Ronda S. Henry-Tillman, MD, FACS; Julie A. Margenthaler, MD, FACS |
| 8:10 AM | Understanding Molecular Subtypes and Those That Are Most Likely to Benefit From Endocrine Therapy
Toan T. Nguyen, MD, FACS |
| 8:30 AM | Landmark Trials of Neoadjuvant Endocrine Therapy and When to Consider for Your Patient
Julie A. Margenthaler, MD, FACS |
| 8:50 AM | Assessing Response to Neoadjuvant Endocrine Therapy and Its Impact on Adjuvant Treatment
Anna Weiss, MD, FACS |
| 9:10 AM | Audience Polling and Discussion: Who Should Prescribe and for Which Patients?
Amy Cyr, MD, FACS; Ronda S. Henry-Tillman, MD, FACS; Julie A. Margenthaler, MD, FACS; Daniela A. Ochoa, MD, FACS |
| 9:40 AM | Break
|
| 10:00 AM | Landmark Trials of Adjuvant Endocrine Therapy
Daniela A. Ochoa, MD, FACS |
| 10:20 AM | Genomic Assays: Interpretation of Results and How It Impacts the Adjuvant Therapy for Your Patient
Nathalie G. Johnson, MD, FACS |
| 10:40 AM | Endocrine Therapy for Unique Populations: Male Patients, Poor surgical candidates
Ronda S. Henry-Tillman, MD, FACS |
| 11:00 AM | Side Effects of Endocrine Therapy and Managing Patient Symptoms
Amy Cyr, MD, FACS |
| 11:20 AM | Case Presentation and Panel Discussion
Amy Cyr, MD, FACS; Ronda S. Henry-Tillman, MD, FACS; Julie A. Margenthaler, MD, FACS; Daniela A. Ochoa, MD, FACS |
| 11:50 AM | Final Remarks and Take-home Message
Ronda S. Henry-Tillman, MD, FACS; Julie A. Margenthaler, MD, FACS |
| 12:00 PM | Adjourn
|
